Merck Of Germany’s Garijo Highlights COVID-19 Vaccine Effective In Mavenclad-Treated MS
COVID-Related Solutions Drive Growth In Q1
Merck KGaA’s short-course oral MS therapy Mavenclad may gain a boost from new data suggesting its use does not affect the beneficial response of patients to COVID-19 vaccines, as the research and manufacturing reagents and solutions business unit of the diversified big pharma reported a strong first quarter due to pandemic-related demand.
You may also be interested in...
Bavencio’s Survival Benefit Confirmed In Front-Line Maintenance Therapy For Advanced Urothelial Cancer
Further details of Merck KGaA/Pfizer-funded JAVELIN Bladder 100 study presented at this year’s ASCO confirm avelumab’s survival benefit when used as front-line maintenance therapy in patients with advanced urothelial cancer that has not progressed following initial chemotherapy.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Europe’s strengths in the biotech space include world-class science, but the continent needs to build on its strengths in order to deliver on the promise of a coming “golden age” of biotech, says a recent report.